Molecular Partners AG ADR (MOLN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $112.71M
Last updated: Nov 17, 2026 at 4:10 PM ET
Molecular Partners AG ADR (MOLN) Statistics
Molecular Partners AG ADR (MOLN) has a market cap of $112.71M. It earned CHF -54.19M on revenue of CHF 0 over the last 12 months.
Total Valuation
| Market Cap | $112.71M |
|---|---|
| Latest price (Nov 17, 2026) | $2.77 |
Key Dates
| Last Earnings Date | Oct 29, 2026 |
|---|---|
| Fiscal Year End | December |
Price Statistics
The stock is down 34.36% over 52 weeks and trades 24.93% below its 50-day average.
| Beta (1Y) | 0.56 |
|---|---|
| 52-Week Change | -34.36% |
| 1-Month Change | -24.32% |
| 3-Month Change | -36.03% |
| 6-Month Change | -25.94% |
| 5-Year Change | -80.76% |
| Total Return (1Y) | -34.36% |
| Total Return (3Y CAGR) | -13.90% |
| Total Return (5Y CAGR) | -22.64% |
| Return vs SPY (1Y) | -44.33% |
| Max Drawdown (1Y) | -47.34% |
| Max Drawdown (3Y) | -75.49% |
| Sharpe Ratio (1Y) | -0.77 |
| Correlation with SPY (1Y) | 0.15 |
| 50-Day Average | $3.69 |
| 200-Day Average | $4.11 |
| 52-Week Range | $2.63 to $5.36 |
| RSI (14 Days) | 27.1 |
| Average Volume (20 Days) | 2.08K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 6.46x current liabilities.
| Current Ratio | 6.46x |
|---|---|
| Quick Ratio | 6.46x |
| Interest Coverage | -1462.23x |
Returns and Efficiency
Return on equity is -110.77% over the last 12 months, against a 5-year average of -31.87%.
| Return on Equity (ROE) | -110.77% |
|---|---|
| Return on Assets (ROA) | -86.98% |
| ROE (5Y Average) | -31.87% |
| ROA (5Y Average) | -23.54% |
| ROIC (5Y Average) | -31.29% |
Scores
MOLN has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was CHF 0 over the last 12 months.
| Revenue | CHF 0 |
|---|---|
| Gross Profit | CHF -22.63M |
| Operating Income | CHF -54.89M |
| Pretax Income | CHF -54.18M |
| Net Income | CHF -54.19M |
| EBITDA | CHF -52.12M |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 78.52% of the CHF 64.52M in total assets.
| Working Capital | CHF 51.32M |
|---|---|
| Shareholder Equity | CHF 50.66M |
| Total Assets | CHF 64.52M |
| Total Liabilities | CHF 13.85M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | CHF -49.24M |
|---|---|
| Depreciation and Amortization | CHF 2.11M |
Trailing 12 months through Sep 30, 2026.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About MOLN
What is MOLN's market cap?
Molecular Partners AG ADR has a market cap of $112.71M.
How many shares of MOLN are outstanding?
Molecular Partners AG ADR has 38.33M shares outstanding. The count is up 2.48% from a year earlier.
Does MOLN pay a dividend?
No. Molecular Partners AG ADR does not pay a dividend.
MOLN pages: Overview, Charting, Financials, Statistics, Competitors